September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Deleted in Liver Cancer-1 (DLC-1) is highly expressed in conjunctival squamous neoplasia and acts as an oncogene in high grade lesions
Author Affiliations & Notes
  • Marina Gomes Pereira Sardinha
    Ocular Pathology, The Henry C.Witelson Ocular Pathology Laboratory, Sao Paulo, Sao Paulo, Brazil
  • Mariana Souza
    Ocular Pathology, The Henry C.Witelson Ocular Pathology Laboratory, Sao Paulo, Sao Paulo, Brazil
  • Marcelo Sobrinho
    Ocular Pathology, The Henry C.Witelson Ocular Pathology Laboratory, Sao Paulo, Sao Paulo, Brazil
  • Carlos Augusto Moreira
    Ocular Pathology, The Henry C.Witelson Ocular Pathology Laboratory, Sao Paulo, Sao Paulo, Brazil
  • Adel Helmi
    Ocular Pathology, The Henry C.Witelson Ocular Pathology Laboratory, Sao Paulo, Sao Paulo, Brazil
  • Miguel N Burnier
    Ocular Pathology, The Henry C.Witelson Ocular Pathology Laboratory, Sao Paulo, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships   Marina Sardinha, None; Mariana Souza, None; Marcelo Sobrinho, None; Carlos Moreira, None; Adel Helmi, None; Miguel Burnier, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2408. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marina Gomes Pereira Sardinha, Mariana Souza, Marcelo Sobrinho, Carlos Augusto Moreira, Adel Helmi, Miguel N Burnier; Deleted in Liver Cancer-1 (DLC-1) is highly expressed in conjunctival squamous neoplasia and acts as an oncogene in high grade lesions. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2408.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Deleted in Liver Cancer-1 gene (DLC1) encodes a Rho GTPase-activating protein 7 that participates in signaling pathways that regulate cytoskeletal changes. It was first described as a tumor suppressor gene in hepatocellular carcinoma and later described in several other tumors. Recently, DLC1 deletion in squamous cell carcinoma from the head and neck area has been reported. The aim of this study is to evaluate a possible role of DLC1 expression in the development and progression of ocular surface squamous neoplasia (OSSN).

Methods : Seven normal human eyes (NHE) obtained from the Eyebank of Canada and 68 OSSN, including 18 papillomas (Pa), 21 conjunctival intraepithelial neoplasia (CIN) I, 11 CIN II, 7 CIN III, and 11 squamous carcinoma (sqCA) were evaluated by immunohistochemistry against DLC-1, using an automated immunostaining protocol. The German immunoreactive score (IRS [0-12] = intensity [0-3] x extension [0-4]) was used to evaluate staining. The Student's t-test and analysis of variances (ANOVA) with Tukey post-hoc test were used to compare mean IRS between groups.

Results : DLC1 was expressed in all NHE (IRS=3.0±1.8), papillomas (IRS=5.6±3.1), CIN I (IRS=5.1±3.1), CIN II (8.3±3.3), CIN III (11±1.7) and SqCA (IRS=10.1±2.9). Furthermore, the IRS in the high grade lesions group (CIN II, III and SqCA) was significantly higher than the normal conjunctiva, Pa and CIN I group (ANOVA; P<0.0001). However, no IRS differences were noted within the low grade group (CIN I, papillomas or NHE) or within the high grade group.

Conclusions : To the best of our knowledge this is the first study of DLC1 expression in OSSN. DLC1 is highly expressed in high grade squamous conjunctival neoplastic processes. DLC1 may act as an oncogene rather than a tumor suppressor, as opposed to squamous cell carcinoma of the head and neck region, and may play a role in OSSN pathogenesis development.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×